All News
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX.
Read Article
Just Can’t Get Enough of Hydroxychloroquine
When it comes to hydroxychloroquine dosing, issues on efficacy, toxicity and therapeutic thresholds may affect the optimal use of this important drug.
Following are three abstracts presented during the meeting that address these topics.
1602 pemphigus pts Rx w/ rituximab vs azathioprine or MMF. RTX pts had lower risk of MI (RR 0.45; P = .01), CVA (RR, 0.42; P < .001), PVD (0.47), HTN (0.48), hyperlipidemia (0.45), NIDDM (0.63), obesity (0.49). Mortality equal betw groups https://t.co/uvDDU5z8gp https://t.co/kJAg5xRKHz
Links:
Dr. John Cush RheumNow ( View Tweet)
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/GQEp8N0uZb https://t.co/TxfyIemzBT
Links:
Dr. John Cush RheumNow ( View Tweet)
NRMP Results for rheumatology 2022 :
- Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied)
- Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied)
WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/YpMhTPnDM4 https://t.co/Aa3EV57yij
Links:
Dr. John Cush RheumNow ( View Tweet)
AURORA1 RCT
📍Efficacy of voclosporin in LN III-V with UPC > 1.5g
💊VOC 23.7 mg BID vs. PCB
💊All got MMF 1g BID and GC
🥇#1 outcome: UPC < 0.5, stable 🫘 fx, ❌ GC > 10 mg
-40% VOC v. 23% PCB (sig)
-all measures favored VOC, but only sig. for UPC < 0.5
Catherine Sims, MD DrCassySims ( View Tweet)
Topic Podcasts - JAK TYK2
https://t.co/DqfEj955aw https://t.co/HRj28berzF
Links:
Dr. John Cush RheumNow ( View Tweet)
A great read from Dr. Anthony Fauci as he steps down from leading the NIH NIAID research for nearly 40 years. He writes on pundits, need for specialty growth, evolution of vaccines and "it aint over till its over" is now "its never over" https://t.co/z0noGckIvx https://t.co/DJKG88V1mc
Links:
Dr. John Cush RheumNow ( View Tweet)
Estimated worldwide market for DMARDs in 2022 was $20.7 billion USD and is expected to rise at a 3.5% annual growth rate to $ 272 billion USD by 2030 https://t.co/futp7249rF https://t.co/QgxJR7TQNw
Links:
Dr. John Cush RheumNow ( View Tweet)
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22.
https://t.co/PPXiX8MG6m https://t.co/Uy0kQd7XGz
Links:
Dr. John Cush RheumNow ( View Tweet)
Fertility issues in SpA
Dr. Sheila Reyes ( @RHEUMarampa) speaks with Dr. Sabrina Hamroun about abstract 1673 at #ACR22.
https://t.co/SvCuE4fx04 https://t.co/DAveKT29J8
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Race play a role in Mycophenolate Response in Scleroderma
Dr. Eric Dein ( @ericdeinmd) speaks with Dr. Lauren Smith about abstract 0521 at #ACR22.
https://t.co/3lcVjfMsub https://t.co/P3XcsiXgWa
Links:
Dr. John Cush RheumNow ( View Tweet)
Copays Reduce Adherence to SLE Medications
Dr. Michael Putman ( @EBRheum) reports on abstract 1115 at #ACR22 Convergence in Philadelphia, PA.
https://t.co/VLyMTSLFCf https://t.co/0nOA0b1576
Links:
Dr. John Cush RheumNow ( View Tweet)
Proceedings of the Royal Society of Medicine and Fibromyalgia Action UK Webinar: Fibromyalgia in the 21st century: Redefining care. https://t.co/6k4Thx4ZSN https://t.co/1TfapVGMoe
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 1207 joints in 55 RA pts shows that Xray progression over 2 yrs is significantly assoc w/ US Power Doppler (OR 2.92), erosions (OR 4.74), but also with Joint tenderness w/o swelling (OR 1.85) ! (Less signif w/ PsA) https://t.co/gue5jt6Xdx https://t.co/vhFBWTgEHW
Links:
Dr. John Cush RheumNow ( View Tweet)
Mayo LUMEN study looked at SLE nephritis incidence betw 1976 -2018, & showed that LN increased over past 4 decades. LN patients have poor outcomes w/ higer rates of ESRD & mortality rates (SMR 6.33); @10 yr survival =70% & 13% ESRD https://t.co/QDDTORSgyZ https://t.co/89ldzxhuMk
Links:
Dr. John Cush RheumNow ( View Tweet)
Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA
Early diagnosis of AxSpA remains a challenge. Strategies to identify patients with suspected inflammatory back pain in the general population is critical.
https://t.co/LsKOOHDOJI https://t.co/NARG61vBSn
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual inhibition of IL17A and IL17F in AxSpA
https://t.co/OvzQnYw7dH https://t.co/qkCsyBofDJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Do different genders experience PsA differently?
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.
Dr. Petryna ( @DrPetryna) weighs in. #ACR22
https://t.co/nPHf2fR6gQ https://t.co/CcO2gwgh3Y
Links:
Dr. John Cush RheumNow ( View Tweet)
Advancing Telehealth in Rheumatology #ACR22
https://t.co/TZL2ZHVTax https://t.co/4Z5Sbvpo23
Links:
Dr. John Cush RheumNow ( View Tweet)
